IPP Bureau
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
By IPP Bureau - March 12, 2022
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
China approves BeiGene’s tislelizumab
By IPP Bureau - March 12, 2022
Tislelizumab is now approved for seven indications in China
BioPharma’s Herceptin biosimilar Phase 3 results positive
By IPP Bureau - March 12, 2022
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Study shows Pfizer vaccine moderately effective against Omicron for children 5-15
By IPP Bureau - March 12, 2022
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Moderna begins Phase 2 study of Omicron-specific bivalent booster
By IPP Bureau - March 11, 2022
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases
By IPP Bureau - March 11, 2022
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Daiichi Sankyo commits US $1 million humanitarian aid to Ukraine
By IPP Bureau - March 11, 2022
The money will be donated to the United Nations Children’s Fund (UNICEF)
Amity awards Dr Azad Moopen Doctorate for Philanthropy
By IPP Bureau - March 11, 2022
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
Aurobindo Pharma trains its managers to be `future ready’
By IPP Bureau - March 11, 2022
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
Emmes acquires Casimir, its fourth major acquisition
By IPP Bureau - March 11, 2022
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
By IPP Bureau - March 11, 2022
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Cancer surgeons gather in Delhi to learn new cancer therapies
By IPP Bureau - March 11, 2022
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Strides receives USFDA approval for Colchicine tablets
By IPP Bureau - March 11, 2022
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
USFDA approves Lupin’s Vigabatrin oral solution
By IPP Bureau - March 11, 2022
The product will be manufactured at Lupin’s facility in Goa, India
Medical devices production under PLI scheme gets off the ground
By IPP Bureau - March 10, 2022
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
